‘Significant risks’: Medicos’ warning to Minns on pharmacist prescribing

NSW plans to expand pharmacists’ autonomous prescribing powers beyond limited treatments. The proposed areas include ear infections, wound care, hypertension and chronic obstructive pulmonary disease. The change matters because these conditions can require more than a straightforward medicine choice. They may involve diagnosis, risk assessment and follow-up.

The medical organisations behind the warning say practitioners must understand a patient’s history and identify the correct condition before prescribing. They argue that pharmacist prescribing in this territory is materially different and carries significant risks for patient outcomes. Fred Betros called the proposal a form of healthcare substitution.

The Pharmacy Guild disputes that view. It says prescribing pharmacists receive extra training in differential diagnosis, history taking and clinical assessment. Health Minister Ryan Park says expanding the scope would improve timely access and reduce pressure on GPs. The proposed model remains contested, especially over how continuity with regular doctors would work.

Pharmacist prescribing gives a pharmacist authority to assess a patient, identify a condition and prescribe treatment. It is an active clinical decision, not simply the supply of medicine. That distinction matters because prescribing requires judgment about diagnosis, suitability, risks and follow-up.

Under ordinary dispensing, a doctor or another authorised prescriber has already selected the medicine and dose. The pharmacist checks, prepares and supplies it, while also providing advice about safe use. Under autonomous prescribing, the pharmacist makes the treatment decision directly. The article says prescribing pharmacists receive extra training in differential diagnosis, medical history-taking and clinical assessment.

Supporters say consultations occur privately and details can be shared with a patient’s GP. Critics argue this may create only a facade of clinical assessment without equivalent medical expertise. NSW Health stresses communication and collaboration with regular GPs to support safe prescribing and continuity of care.

The article does not state how many people in NSW have already received treatment from prescribing pharmacists. It also gives no estimate of how many pharmacists are expected to qualify by the end of the year. Those figures cannot be reliably calculated from the information provided.

The source does mention a separate federal 12-month trial covering pharmacist consultations and medicines for urinary tract infections and oral contraceptives. It does not say how many patients will use that trial, nor does it connect those services to a NSW total. Confusing those details with the requested figures would risk overstating the evidence.

What the article does establish is that NSW announced broader pharmacist prescribing powers in September. The Pharmacy Guild says one in four people waits an unacceptable time for a GP appointment, while medical groups are demanding a pause. The scale of current use and future qualification remains unstated here.

When pharmacists prescribe for conditions such as hypertension or chronic obstructive pulmonary disease, a wrong or incomplete assessment could delay the right care. These conditions may involve other illnesses, medicine interactions or changing symptoms. The medical organisations say safe treatment requires patient history, expert diagnosis and continuity with a regular practitioner.

A concrete warning comes from the medical indemnity insurer Avant. It called for a pause after a report found that one in five patients suffered a serious injury in a prescribing-related incident. The article does not link every injury to pharmacists, but the figure illustrates why prescribing decisions and follow-up matter. Poor safety-netting could also leave patients without clear advice about worsening symptoms.

The Pharmacy Guild says pharmacists receive training in differential diagnosis and clinical assessment. NSW Health says pharmacists should communicate with regular GPs. The dispute therefore centres on whether safeguards and collaboration can make expanded prescribing safe enough for more complex conditions.

William Terry Obeng, a British prescribing pharmacist, was suspended for six months after a hearing found unsafe prescribing. One case resulted in a fatal overdose. The incident intensified concerns about whether pharmacists prescribing independently can identify risks that need broader medical assessment.

The hearing found that Obeng had failed to adequately consider medication dependence and misuse. He also failed to refer patients back to their GPs for appropriate assessment and did not put adequate safety-netting in place. Most of his prolific prescribing was done online, which created circumstances the article says are unlikely to be replicated in Australia, where consultations occur in person.

The case does not prove that every pharmacist-prescribing model is unsafe. It does show why diagnosis, referral and follow-up safeguards matter. Australian debate now focuses on whether in-person consultations, extra training and GP communication can prevent comparable failures as prescribing powers expand.

Collaborative care keeps pharmacists and doctors involved in the same treatment process. Pharmacists may prescribe for selected conditions, but under a doctor’s supervision. Autonomous prescribing is broader: the pharmacist assesses and treats the patient without direct medical supervision for that episode. The difference is who carries the clinical decision-making relationship and how quickly a doctor becomes involved.

Fred Betros supports collaborative care but opposes the proposed expansion. He says pharmacists can prescribe safely in supervised models, while complex conditions need medical expertise. NSW Health similarly highlights communication with a patient’s regular GP to support safe prescribing and continuity.

Autonomous prescribing could offer faster access when GP appointments are unavailable. The Pharmacy Guild says it gives patients another safe option and frees GPs for complex and chronic cases. Critics fear that independent assessment may miss diagnoses or warning signs. The article leaves that safety question unresolved.

Medicare is the federal system used to subsidise eligible medical services and medicines. The article describes its subsidy process as strict and says funding proposals normally require assessment by an independent expert committee. That process is intended to provide formal evaluation before public money supports a service or treatment.

The federal government announced a 12-month trial covering pharmacist consultations and subsidised medicines for urinary tract infections and oral contraceptives. Instead of using Medicare’s usual subsidy system, it will draw on the government’s $792.9 million women’s health package. The funding route is therefore separate from the assessment pathway described in the article.

This matters because the medical groups say bypassing that system reduces the role of independent scrutiny. The article does not conclude that the trial is unsafe. It shows, however, that pharmacist prescribing is being funded through a different mechanism while NSW considers broader powers and medical organisations seek a pause.